Clinical Research
Second-line
Weekly Paclitaxel in Patients with Inoperable NSCLC Who Fail Combination
Chemotherapy With Cisplatin (PubMed)
Phase II study published in the August issue of Lung Cancer that
found second-line treatment with single-agent paclitaxel is well-tolerated,
active and associated with long survivals in inoperable NSCLC patients
whose disease does not respond or recurs following standard front-line
platinum-based chemotherapy. [8/04]
Single
Agent Paclitaxel in the Treatment of Advanced NSCLC (The
Oncologist)
by Mark A. Socinski
v.4, no.5 The Oncologist (October 1999): 408-416
Reviews the role of paclitaxel in the treatment of advanced NSCLC,
including single agent paclitaxel in the first-line setting, one-hour
and three-hour single agent paclitaxel, weekly paclitaxel, paclitaxel
vs. best supportive care, and paclitaxel in the second-line setting. Concludes
that single agent paclitaxel is highly active in advanced, metastatic
NSCLC and notes that the major toxicities include neutropenia, neuropathy,
and myalgia/arthralgia syndrome. [10/99]
Taxol
(paclitaxel) - Recent MEDLINE Abstracts (PubMed)
Taxol
(paclitaxel) - Clinical Trials (PubMed)
Side Effects
Taxol
(paclitaxel) (CancerBACUP)
Describes Taxol (also known as paclitaxel), how it works and what side
effects to expect during and after treatment. [11/02]
Paclitaxel (Taxol) & Carboplatin
Prolonged Taxol
(Paclitaxel) Plus Carboplatin (Paraplatin) Improves Anti-Cancer Therapy
(Doctor's Guide)
Reports results of a study presented at the 9th World Congress on
Lung Cancer that found a novel weekly regimen of Taxol and carboplatin
offers a safe and effective treatment option for patients with advanced
NSCLC. Based on results of this Phase II study, a Phase III trial has
begun comparing the standard regimen of Taxol plus carboplatin every three
weeks to the aforementioned weekly regimen. [9/00]
Paclitaxel (Taxol) & Cisplatin
Phase
I/II Study of Cisplatin Combined with Weekly Paclitaxel in Patients with
Advanced NSCLC (PubMed)
Abstract of a study reported in the March 22, 2004 issue of the British
Journal Of Cancer that found encouraging results in treating stage
IIIB/IV NSCLC patients with paclitaxel and cisplatin. The progression-free
survival, the median survival time, and the 1-year survival rate were
5.5 months, 13.7 months, and 56.9%, respectively. Concludes the regimen
is tolerable and very active against advanced NSCLC and recommends a Phase
III study. [3/04]
Comparison
of Survival and Quality of Life in Advanced NSCLC Patients Treated with
Paclitaxel Combined with Cisplatin versus Etoposide with Cisplatin
(PubMed)
Summarizes study results reported in the February 2000 issue of
the Journal of Clinical Oncology that showed, with regard
to survival, the combination of paclitaxel-cisplatin is superior to etoposide-cisplatin
in patients with stage IIIB and stage IV NSCLC. Registration necessary
for free access to Medscape. [2/00]
Phase
II Trial of Paclitaxel by 96-Hour Continuous Infusion in Combination with
Cisplatin for Patients with Advanced NSCLC (PubMed)
Summarizes study results reported in the July 2000 issue of Clinical
Cancer Research that showed prolonged continuous infusion
of paclitaxel (Taxol) in combination with cisplatin does not appear to
be obviously superior to shorter infusion times for patients with advanced
NSCLC. [7/00]
Paclitaxel (Taxol) & Vinorelbine
(Navelbine)
Non-platinum
Regimen Appears Active in Advanced NSCLC (cancernetwork.com)
v.9, no.12 Oncology News (December 2000)
Reports results of phase I/II studies presented at the 9th World Congress
on Lung Cancer that found a regimen of paclitaxel (Taxol) and vinorelbine
(Navelbine) in NSCLC appears to yield results similar to those with platinum-based
regimens. Registration required for free access to cancernetwork.com.
[12/00]
Paclitaxel (Taxol) for SCLC
Adding
Paclitaxel May Improve Survival in Limited-Disease SCLC
(cancernetwork.com)
v.9,no.9 Oncology News (September 2000)
Summarizes study results presented at the 36th annual ASCO meeting that
showed the addition of paclitaxel (Taxol) to etoposide plus cisplatin
(Platinol), with concurrent thoracic radiotherapy, may improve survival
in patients with limited SCLC. Registration required for free access to
cancernetwork.com. [9/00]
|
